Hippo/YAP pathway for targeted therapy

Translational Lung Cancer Research

Volumn 3, Issue 2, 2014, Pages 75-83

  Felley Bosco, Emanuela ^a   Stahel, Rolf ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Hippo pathway; Malignant pleural mesothelioma (MPM); Yes associated protein (YAP) oncogene

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; LYSOPHOSPHATIDIC ACID RECEPTOR; MERLIN; SONIC HEDGEHOG PROTEIN; SURVIVIN; THROMBIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VERTEPORFIN; YES ASSOCIATED PROTEIN;

CELL CYCLE; DOWN REGULATION; ENZYME ACTIVATION; HIPPO SIGNALING PATHWAY; HUMAN; MOLECULARLY TARGETED THERAPY; PLEURA MESOTHELIOMA; PROTEIN FUNCTION; PROTEIN INDUCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84941614848     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2014.02.03     Document Type: Review

References (92)

1. Huang J, Wu S, Barrera J, et al. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 2005;122:421-34.
2. Badouel C, Garg A, McNeill H. Herding Hippos: regulating growth in flies and man. Curr Opin Cell Biol 2009;21:837-43.
3. Tapon N, Harvey KF, Bell DW, et al. Salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 2002;110:467-78.
4. Zhao B, Lei QY, Guan KL. The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol 2008;20:638-46.
5. Yin F, Yu J, Zheng Y, et al. Spatial organization of hippo signaling at the plasma membrane mediated by the tumor suppressor merlin/NF2. Cell 2013;154:1342-55.
6. Striedinger K, VandenBerg SR, Baia GS, et al. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia 2008;10:1204-12.
7. Zhao B, Ye X, Yu J, et al. TEAD mediates YAPdependent gene induction and growth control. Genes Dev 2008;22:1962-71.
8. Pobbati AV, Hong W. Emerging roles of TEAD transcription factors and its coactivators in cancers. Cancer Biol Ther 2013;14:390-8.
9. Xu MZ, Chan SW, Liu AM, et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 2011;30:1229-40.
10. Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007;130:1120-33.
11. Lu L, Li Y, Kim SM, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A 2010;107:1437-42.
12. Zender L, Spector MS, Xue W, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006;125:1253-67.
13. Xu MZ, Yao TJ, Lee NP, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009;115:4576-85.
14. Zhang X, George J, Deb S, et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene 2011;30:2810-22.
15. Muramatsu T, Imoto I, Matsui T, et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis 2011;32:389-98.
16. Wang Y, Dong Q, Zhang Q, et al. Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 2010;101:1279-85.
17. Fernandez-L A, Northcott PA, Dalton J, et al. YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev 2009;23:2729-41.
18. Modena P, Lualdi E, Facchinetti F, et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol 2006;24:5223-33.
19. Snijders AM, Schmidt BL, Fridlyand J, et al. Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene 2005;24:4232-42.
20. Avruch J, Zhou D, Bardeesy N. YAP oncogene overexpression supercharges colon cancer proliferation. Cell Cycle 2012;11:1090-6.
21. Seidel C, Schagdarsurengin U, Blumke K, et al. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog 2007;46:865-71.
22. Jiang Z, Li X, Hu J, et al. Promoter hypermethylationmediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res 2006;56:450-8.
23. Takahashi Y, Miyoshi Y, Takahata C, et al. Downregulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 2005;11:1380-5.
24. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer 2013;13:246-57.
25. Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007;21:2747-61.
26. Halder G, Dupont S, Piccolo S. Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat Rev Mol Cell Biol 2012;13:591-600.
27. Yu FX, Zhao B, Panupinthu N, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012;150:780-91.
28. Yu FX, Zhang Y, Park HW, et al. Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. Genes Dev 2013;27:1223-32.
29. Mo JS, Yu FX, Gong R, et al. Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). Genes Dev 2012;26:2138-43.
30. Wang Z, Wu Y, Wang H, et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci U S A 2014;111:E89-98.
31. Carbone M, Yang H. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res 2012;18:598-604.
32. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002;29:2-17.
33. Park EK, Takahashi K, Hoshuyama T, et al. Global magnitude of reported and unreported mesothelioma. Environ Health Perspect 2011;119:514-8.
34. Carbone M, Ly BH, Dodson RF, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 2012;227:44-58.
35. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-603.
36. Jaurand MC. Mechanisms of fiber-induced genotoxicity. Environ Health Perspect 1997;105 Suppl 5:1073-84.
37. Mossman B, Light W, Wei E. Asbestos: mechanisms of toxicity and carcinogenicity in the respiratory tract. Annu Rev Pharmacol Toxicol 1983;23:595-615.
38. Miserocchi G, Sancini G, Mantegazza F, et al. Translocation pathways for inhaled asbestos fibers. Environ Health 2008;7:4.
39. Donaldson K, Murphy FA, Duffin R, et al. Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Part Fibre Toxicol 2010;7:5.
40. Kamp DW. Asbestos-induced lung diseases: an update. Transl Res 2009;153:143-52.
41. Heintz NH, Janssen-Heininger YM, Mossman BT. Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol 2010;42:133-9.
42. Sekido Y. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci 2010;101:1-6.
43. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004;432:324-31.
44. Carmona R, Cano E, Grueso E, et al. Peritoneal repairing cells: a type of bone marrow derived progenitor cells involved in mesothelial regeneration. J Cell Mol Med 2011;15:1200-9.
45. Lansley SM, Searles RG, Hoi A, et al. Mesothelial cell differention into osteoblast-and adipocyte-like cells. J Cell Mol Med 2011;15:2095-105.
46. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005;115:1503-21.
47. Cai J, Zhang N, Zheng Y, et al. The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev 2010;24:2383-8.
48. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011;39:D945-50.
49. Kratzke RA, Otterson GA, Lincoln CE, et al. Immunohistochemical analysis of the p16INK4 cyclindependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 1995;87:1870-5.
50. Yang CT, You L, Yeh CC, et al. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 2000;92:636-41.
51. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994;54:5547-51.
52. Xio S, Li D, Vijg J, et al. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995;11:511-5.
53. Prins JB, Williamson KA, Kamp MM, et al. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 1998;75:649-53.
54. Toyooka S, Pass HI, Shivapurkar N, et al. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res 2001;61:5727-30.
55. Wong L, Zhou J, Anderson D, et al. Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer 2002;38:131-6.
56. Destro A, Ceresoli GL, Baryshnikova E, et al. Gene methylation in pleural mesothelioma: Correlations with clinico-pathological features and patient's follow-up. Lung Cancer 2008;59:369-76.
57. Bianchi AB, Mitsunaga SI, Cheng JQ, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A 1995;92:10854-8.
58. Sekido Y, Pass HI, Bader S, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995;55:1227-31.
59. Deguen B, Goutebroze L, Giovannini M, et al. Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene. Int J Cancer 1998;77:554-60.
60. Jin H, Sperka T, Herrlich P, et al. Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature 2006;442:576-9.
61. Thurneysen C, Opitz I, Kurtz S, et al. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 2009;64:140-7.
62. Tang X, Jang SW, Wang X, et al. Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nat Cell Biol 2007;9:1199-207.
63. Fleury-Feith J, Lecomte C, Renier A, et al. Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours. Oncogene 2003;22:3799-805.
64. Lecomte C, Andujar P, Renier A, et al. Similar tumor suppressor gene alteration profiles in asbestosinduced murine and human mesothelioma. Cell Cycle 2005;4:1862-9.
65. Jongsma J, van Montfort E, Vooijs M, et al. A conditional mouse model for malignant mesothelioma. Cancer Cell 2008;13:261-71.
66. Zhang N, Bai H, David KK, et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 2010;19:27-38.
67. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997;386:761, 763.
68. Curto M, McClatchey AI. Nf2/Merlin: a coordinator of receptor signalling and intercellular contact. Br J Cancer 2008;98:256-62.
69. Curto M, Cole BK, Lallemand D, et al. Contactdependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol 2007;177:893-903.
70. McLaughlin ME, Kruger GM, Slocum KL, et al. The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion. Proc Natl Acad Sci U S A 2007;104:3261-6.
71. Li W, You L, Cooper J, et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 2010;140:477-90.
72. Lau YK, Murray LB, Houshmandi SS, et al. Merlin is a potent inhibitor of glioma growth. Cancer Res 2008;68:5733-42.
73. Murakami H, Mizuno T, Taniguchi T, et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res 2011;71:873-83.
74. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011;43:668-72.
75. Ren YR, Patel K, Paun BC, et al. Structural analysis of the cancer-specific promoter in mesothelin and in other genes overexpressed in cancers. J Biol Chem 2011;286:11960-9.
76. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992;50:373-81.
77. Ordóñez NG. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update. Hum Pathol 2013;44:1-19.
78. Mizuno T, Murakami H, Fujii M, et al. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene 2012;31:5117-22.
79. Dixit R, Ai X, Fine A. Derivation of lung mesenchymal lineages from the fetal mesothelium requires hedgehog signaling for mesothelial cell entry. Development 2013;140:4398-406.
80. Shi Y, Moura U, Opitz I, et al. Role of hedgehog signaling in malignant pleural mesothelioma. Clin Cancer Res 2012;18:4646-56.
81. Hao Y, Chun A, Cheung K, et al. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 2008;283:5496-509.
82. Romer JT, Kimura H, Magdaleno S, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 2004;6:229-40.
83. Tanaka I, Osada H, Fujii M, et al. LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade. Oncogene 2013. [Epub ahead of print].
84. Goyal RK, Lin P, Kanungo J, et al. Ajuba, a novel LIM protein, interacts with Grb2, augments mitogen-activated protein kinase activity in fibroblasts, and promotes meiotic maturation of Xenopus oocytes in a Grb2-and Rasdependent manner. Mol Cell Biol 1999;19:4379-89.
85. Das Thakur M, Feng Y, Jagannathan R, et al. Ajuba LIM proteins are negative regulators of the Hippo signaling pathway. Curr Biol 2010;20:657-62.
86. Liu-Chittenden Y, Huang B, Shim JS, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 2012;26:1300-5.
87. Keshava S, Sahoo S, Tucker TA, et al. Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor. Cancer Res 2013;73:3963-73.
88. O'Callaghan K, Kuliopulos A, Covic L. Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J Biol Chem 2012;287:12787-96.
89. Yamada T, Yano S, Ogino H, et al. Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2. Cancer Sci 2008;99:1603-10.
90. Shi Y, Felley-Bosco E, Marti TM, et al. Differential effects of lovastatin on cisplatin responses in normal human mesothelial cells versus cancer cells: implication for therapy. PLoS One 2012;7:e45354.
91. Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov 2014;13:63-79.
92. Park HW, Guan KL. Regulation of the Hippo pathway and implications for anticancer drug development. Trends Pharmacol Sci 2013;34:581-9.